论文部分内容阅读
目的 探讨TACE与经皮肝穿门静脉注射白介素 2联合治疗肝癌并门脉癌栓患者的疗效。方法 2 2例单纯TACE(对照组 ) ,16例TACE联合经皮门静脉注射IL2 治疗 (治疗组 )治疗肝癌 ,有效率和生存期进行对比分析。结果 肝癌瘤体变化 ,两组无明显差异 ;门脉癌栓 ,对照组消失率 4.5 %,缩小 36 .4%,总有效率 40 .9%,治疗组分别为 12 .5 %、5 0 %、6 2 .5 %;生存率 ,对照组 0 .5、1.0、1.5、2 .0年生存率分别为 45 .5 %、2 7.3 %、0和 0 ,治疗组分别为 5 6 .3 %、31.5 %、12 .5 %、6 .3 %,中位生存期分别为 5 .7M和 8.7M ,1.5、2 .0年生存率对比 (P <0 .0 5 )。结论 TACE联合经皮门静脉注射IL2 可提高肝癌并门脉癌栓的疗效 ,延长生存期。
Objective To investigate the curative effect of TACE and percutaneous transhepatic portal vein injection of interleukin-2 in the treatment of patients with hepatocellular carcinoma and portal vein tumor thrombus. Methods Twenty-two simple TACE (control group), 16 TACE combined with percutaneous portal vein injection of IL2 (treatment group) for the treatment of liver cancer, the efficiency and survival were compared. Results There was no significant difference between the two groups. The rate of disappearance of portal vein tumor thrombus and control group was 4.5%, decreased by 36.4% and the total effective rate was 40.9%. The treatment group was 12.5% and 50% , Respectively. The survival rates at 0, 5, 1, 1, 1.5, 2 and 0 years in the control group were 45.5%, 2 7.3%, 0 and 0, respectively, and the treatment groups were respectively 56.3% , 31.5%, 12.5%, 6.3% respectively. The median survival time was 5.7M and 8.7M respectively, and the survival rate at 1.5 and 2.0 years (P <0.05). Conclusion The combination of TACE and percutaneous intra-venous injection of IL2 can improve the curative effect of hepatocellular carcinoma and portal vein tumor thrombus and prolong the survival period.